For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Iterum Therapeutics Plc (NASDAQ: ITRM) closed at $1.54 in the last session, down -7.78% from day before closing price of $1.67. In other words, the price has decreased by -$7.78 from its previous closing price. On the day, 0.51 million shares were traded. ITRM stock price reached its highest trading level at $1.75 during the session, while it also had its lowest trading level at $1.48.
Ratios:
We take a closer look at ITRM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.89 and its Current Ratio is at 1.89.
On March 15, 2021, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $2.50.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on June 02, 2020, whereas the target price for the stock was revised from $7 to $2.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 22 ’23 when Dunne Michael W. bought 25,000 shares for $1.40 per share. The transaction valued at 35,000 led to the insider holds 113,754 shares of the business.
Dunne Michael W. bought 10,000 shares of ITRM for $18,442 on Dec 18 ’23. The Director now owns 88,754 shares after completing the transaction at $1.84 per share. On Nov 22 ’23, another insider, Dunne Michael W., who serves as the Director of the company, bought 20,000 shares for $2.03 each. As a result, the insider paid 40,690 and bolstered with 78,754 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ITRM now has a Market Capitalization of 27432790 and an Enterprise Value of 20876248.
Stock Price History:
The Beta on a monthly basis for ITRM is 2.32, which has changed by 0.39999998 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, ITRM has reached a high of $2.50, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is 1.42%, while the 200-Day Moving Average is calculated to be 18.00%.
Shares Statistics:
According to the various share statistics, ITRM traded on average about 615.91K shares per day over the past 3-months and 130670 shares per day over the past 10 days. A total of 16.43M shares are outstanding, with a floating share count of 16.01M. Insiders hold about 2.52% of the company’s shares, while institutions hold 6.94% stake in the company. Shares short for ITRM as of 1713139200 were 1197109 with a Short Ratio of 1.94, compared to 1710460800 on 1207667. Therefore, it implies a Short% of Shares Outstanding of 1197109 and a Short% of Float of 7.4200004.
Earnings Estimates
Iterum Therapeutics Plc (ITRM) is currently under the scrutiny of 2.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$0.72 for the current quarter, with a high estimate of -$0.57 and a low estimate of -$0.88, while EPS last year was -$0.6. The consensus estimate for the next quarter is -$0.58, with high estimates of -$0.5 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$1.75 and -$2.95 for the fiscal current year, implying an average EPS of -$2.35. EPS for the following year is -$1.03, with 2.0 analysts recommending between -$0.79 and -$1.27.
Revenue Estimates
Based on 2 analysts’ estimates, the company’s revenue will be $12.13M in the next fiscal year. The high estimate is $23.33M and the low estimate is $930k.
